FDA Approves DOXYCYCLINE — Strides Pharma Science Limited

# FDA Approves Doxycycline ANDA for Strides Pharma Science Limited Strides Pharma Science Limited has received FDA approval for its abbreviated new drug application (ANDA065055) for oral doxycycline, expanding the company's generic antibiotic portfolio and enabling it to compete in the established doxycycline market. The approval positions Strides to capture additional market share in the broad-spectrum antibiotic segment, which sees significant demand across multiple therapeutic applications including bacterial infections and dermatological treatments.